Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arch Biopartners Inc (ARCH.VN)

Arch Biopartners Inc (ARCH.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 112,700
  • Shares Outstanding, K 65,906
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,920 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings $-0.01 on 03/03/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend 0.200 on 09/13/00
  • Sector Medical
  • INDUSTRY GROUPING:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.620 +3.70%
on 05/05/25
1.800 -6.67%
on 04/21/25
-0.120 (-6.67%)
since 04/17/25
3-Month
1.270 +32.28%
on 04/07/25
1.940 -13.40%
on 02/21/25
-0.240 (-12.50%)
since 02/20/25
52-Week
1.270 +32.28%
on 04/07/25
2.200 -23.64%
on 10/18/24
-0.020 (-1.18%)
since 05/17/24

Most Recent Stories

More News
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

ARCH.VN : 1.680 (-1.75%)
ACHFF : 1.2000 (-1.64%)
U.S. Eases into Memorial Day Weekend

Monday U.S. Markets are Closed for Memorial Day Tuesday U.S. Economic Lookahead S&P ...

MOMO : 6.17 (-0.64%)
A : 113.21 (-0.20%)
ARCH.VN : 1.680 (-1.75%)
DAC : 85.14 (-1.96%)
HEI.A : 218.55 (-1.69%)
HPQ : 28.96 (-0.48%)
COST : 1,034.19 (-0.01%)
GCO : 22.65 (-1.91%)
EGT.VN : 0.100 (+5.26%)
DAC.VN : 0.035 (+600.00%)
DELL : 113.63 (-0.57%)
CRM : 286.47 (-0.40%)
Stocks in play: Arch Biopartners Inc.

Announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee ...

ARCH.VN : 1.680 (-1.75%)
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage...

ARCH.VN : 1.680 (-1.75%)
ACHFF : 1.2000 (-1.64%)
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.680 (-1.75%)
ACHFF : 1.2000 (-1.64%)
Shares for Interest Debt Settlement

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the...

ARCH.VN : 1.680 (-1.75%)
ACHFF : 1.2000 (-1.64%)
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.680 (-1.75%)
ACHFF : 1.2000 (-1.64%)
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe...

ARCH.VN : 1.680 (-1.75%)
ACHFF : 1.2000 (-1.64%)
Unaware of Any Undisclosed Material Change

TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc....

ARCH.VN : 1.680 (-1.75%)
ACHFF : 1.2000 (-1.64%)
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.680 (-1.75%)
ACHFF : 1.2000 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and...

See More

Key Turning Points

3rd Resistance Point 1.753
2nd Resistance Point 1.737
1st Resistance Point 1.723
Last Price 1.680
1st Support Level 1.693
2nd Support Level 1.677
3rd Support Level 1.663

See More

52-Week High 2.200
Fibonacci 61.8% 1.845
Fibonacci 50% 1.735
Last Price 1.680
Fibonacci 38.2% 1.625
52-Week Low 1.270

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar